RNAM – Avidity Biosciences Inc
RNAM — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
6.18
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
72.82
Target Price
72
Analyst Recom
3
Performance Q
2.13
Upside
N/A
Beta
0.98
Ticker: RNAM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-10 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-11 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-12 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-13 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-17 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-18 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-19 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-20 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-23 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-24 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-25 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-26 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-27 | RNAM | 72.82 | N/A | N/A | 0 |
| 2026-03-30 | RNAM | 72.82 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | RNAM | 0.00 | 0 | 0 |
| 2026-03-10 | RNAM | 0.00 | 0 | 0 |
| 2026-03-11 | RNAM | 0.00 | 0 | 6.18 |
| 2026-03-12 | RNAM | 0.00 | 0 | 6.18 |
| 2026-03-13 | RNAM | 0.00 | 0 | 6.18 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
Beta
0.98
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
Growth Score
Sentiment Score
Actual DrawDown %
Max Drawdown 5-Year %
Target Price
72
P/E
Forward P/E
PEG
P/S
602.56
P/B
6.52
P/Free Cash Flow
EPS
-4.96
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-3650.39
Relative Volume
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
No data found for RNAM
Avidity Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 511
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. As of February 27, 2026, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG.
RNAM
Latest News
—
Caricamento notizie per RNAM…
stock quote shares RNAM – Avidity Biosciences Inc Stock Price stock today
news today RNAM – Avidity Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch RNAM – Avidity Biosciences Inc yahoo finance google finance
stock history RNAM – Avidity Biosciences Inc invest stock market
stock prices RNAM premarket after hours
ticker RNAM fair value insiders trading